Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
PAMNANI, Shitaldas J.
SUDENGA, Staci L.
ROLLISON, Dana E.
INGLES, Donna J.
ABRAHAMSEN, Martha
LAZCANO-PONCE, Eduardo
HUANG, Yangxin
BORENSTEIN, Amy
GIULIANO, Anna R.
Citação
JOURNAL OF INFECTIOUS DISEASES, v.218, n.8, p.1219-1227, 2018
Resumo
Background. The purpose of this study was to assess genital recurrence of human papillomavirus (HPV) genotypes included in the 9-valent vaccine and to investigate factors associated with recurrence among men in the HPV Infection in Men (HIM) Study. Methods. Men were followed every 6 months for a median of 3.7 years. HPV genotypes were detected using Roche linear array. Factors associated with type-specific HPV recurrence (infections occurring after a >= 12-month infection-free period) were assessed. Results. In type-specific analyses, 31% of prior prevalent and 20% of prior incident infections recurred. Among prevalent infections, HPV types 52, 45, 16, 58, and 6 and among incident infections, HPV types 58, 52, 18, 16, and 11 had the highest rates of recurrence. New sexual partners (male or female) and frequency of sexual intercourse with female partners were associated with HPV-6, -16, -31, and -58 infection recurrence. In grouped analyses, lifetime and new male sexual partners were associated with recurrence of prior incident infection with any of the 9 HPV types. Conclusions. Recurrence of genital HPV infections is relatively common among men and associated with high-risk sexual behavior. Further studies are needed to understand the role of HPV recurrence in the etiology of HPV-associated diseases.
Palavras-chave
human papillomavirus, recurrence, redetection, men, HIM Study
Referências
- Arroyo LS, 2013, J CLIN VIROL, V58, P437, DOI 10.1016/j.jcv.2013.07.013
- Barzona L, 2011, J CLIN VIROL, V52, P93, DOI 10.1016/j.jcv.2011.07.006
- Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
- Rodriguez AC, 2012, INT J CANCER, V131, P1874, DOI 10.1002/ijc.27418
- Franceschi S, 2002, BRIT J CANCER, V86, P705, DOI 10.1038/sj/bjc/6600194
- Giuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151
- Giuliano AR, 2015, INT J CANCER, V136, P2752, DOI 10.1002/ijc.29082
- Giuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2
- Gravitt Patti E, 2012, Open Virol J, V6, P198, DOI 10.2174/1874357901206010198
- Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020
- Insinga RP, 2010, CANCER EPIDEM BIOMAR, V19, P1585, DOI 10.1158/1055-9965.EPI-09-1235
- Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044
- Lu BB, 2012, CANCER RES, V72, P676, DOI 10.1158/0008-5472.CAN-11-0751
- Moscicki AB, 2013, J INFECT DIS, V208, P403, DOI 10.1093/infdis/jit175
- Pamnani SJ, 2016, CANCER RES, V76, P6066, DOI 10.1158/0008-5472.CAN-16-0224
- Partridge JM, 2007, J INFECT DIS, V196, P1128, DOI 10.1086/521192
- Perez-Gallego L, 2001, AM J CLIN PATHOL, V116, P143
- Rositch AF, 2012, CANCER RES, V72, P6183, DOI 10.1158/0008-5472.CAN-12-2635
- Smith JS, 2011, J ADOLESCENT HEALTH, V48, P540, DOI 10.1016/j.jadohealth.2011.03.010
- Stevens MP, 2006, J CLIN MICROBIOL, V44, P2428, DOI 10.1128/JCM.02608-05
- Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
- Theiler RN, 2010, OBSTET GYNECOL, V115, P1150, DOI 10.1097/AOG.0b013e3181e00927
- Trottier H, 2010, CANCER RES, V70, P8569, DOI 10.1158/0008-5472.CAN-10-0621
- Winer RL, 2011, CANCER EPIDEM BIOMAR, V20, P699, DOI 10.1158/1055-9965.EPI-10-1108